JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms (original) (raw)

Nature Genetics volume 41, pages 446–449 (2009)Cite this article

Abstract

Chronic myeloproliferative neoplasms (MPNs) are a group of related conditions characterized by the overproduction of cells from one or more myeloid lineages. More than 95% of cases of polycythemia vera, and roughly half of essential thrombocythemia and primary myelofibrosis acquire a unique somatic 1849G>T JAK2 mutation (encoding V617F) that is believed to be a critical driver of excess proliferation1,2,3,4. We report here that _JAK2_V617F-associated disease is strongly associated with a specific constitutional JAK2 haplotype, designated 46/1, in all three disease entities compared to healthy controls (polycythemia vera, n = 192, P = 2.9 × 10−16; essential thrombocythemia, n = 78, P = 8.2 × 10−9 and myelofibrosis, n = 41, P = 8.0 × 10−5). Furthermore, _JAK2_V617F specifically arises on the 46/1 allele in most cases. The 46/1 JAK2 haplotype thus predisposes to the development of _JAK2_V617F-associated MPNs (OR = 3.7; 95% CI = 3.1–4.3) and provides a model whereby a constitutional genetic factor is associated with an increased risk of acquiring a specific somatic mutation.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144–1148 (2005).
    Article CAS Google Scholar
  2. Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779–1790 (2005).
    Article CAS Google Scholar
  3. Levine, R.L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387–397 (2005).
    Article CAS Google Scholar
  4. Baxter, E.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054–1061 (2005).
    Article CAS Google Scholar
  5. Kralovics, R., Guan, Y. & Prchal, J.T. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp. Hematol. 30, 229–236 (2002).
    Article CAS Google Scholar
  6. Jones, A.V. et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106, 2162–2168 (2005).
    Article CAS Google Scholar
  7. Pikman, Y. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3, e270 (2006).
    Article Google Scholar
  8. Kralovics, R. Genetic complexity of myeloproliferative neoplasms. Leukemia 22, 1841–1848 (2008).
    Article CAS Google Scholar
  9. Rumi, E. et al. Disease anticipation in familial myeloproliferative neoplasms. Blood 112, 2587–2588 (2008).
    Article CAS Google Scholar
  10. Landgren, O. et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24, 577 first-degree relatives of 11, 039 patients with myeloproliferative neoplasms in Sweden. Blood 112, 2199–2204 (2008).
    Article CAS Google Scholar
  11. Pardanani, A., Fridley, B.L., Lasho, T.L., Gilliland, D.G. & Tefferi, A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood 111, 2785–2789 (2008).
    Article CAS Google Scholar
  12. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661–678 (2007).
  13. Stephens, M. & Donnelly, P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73, 1162–1169 (2003).
    Article CAS Google Scholar
  14. Cario, H., Goerttler, P.S., Steimle, C., Levine, R.L. & Pahl, H.L. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br. J. Haematol. 130, 800–801 (2005).
    Article CAS Google Scholar
  15. Barrett, J.C. et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955–962 (2008).
    Article CAS Google Scholar
  16. Sandberg, E.M., Wallace, T.A., Godeny, M.D., VonDerLinden, D. & Sayeski, P.P. Jak2 tyrosine kinase: a true jak of all trades? Cell Biochem. Biophys. 41, 207–232 (2004).
    Article Google Scholar
  17. Khoury, M.J., Beaty, T.H. & Cohen, B.H. Fundamentals of Genetic Epidemiology (Oxford University Press, New York, 1993).
  18. Easton, D.F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087–1093 (2007).
    Article CAS Google Scholar
  19. Eeles, R.A. et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 40, 316–321 (2008).
    Article CAS Google Scholar
  20. Di Bernardo, M.C. et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 40, 1204–1210 (2008).
    Article CAS Google Scholar
  21. Jones, A.V. et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107, 3339–3341 (2006).
    Article CAS Google Scholar

Download references

Acknowledgements

This study was supported by Leukaemia Research (UK) Specialist Programme Grant 0280 and makes use (in part) of data generated by the WTCCC. A full list of the investigators who contributed to the generation of the WTCCC data are available from www.wtccc.org.uk, funding for which was provided by the Wellcome Trust under award 076113. We are grateful to P. Strike (Salisbury Research and Development Support Unit) for statistical advice. A.R. was supported by the Deutsche José Carreras Leukämie-Stiftung e.V. - DJCLS R06/02, Germany.

Author information

Authors and Affiliations

  1. Wessex Regional Genetics Laboratory, Salisbury, UK
    Amy V Jones, Andrew Chase, Francis Grand & Nicholas C P Cross
  2. Human Genetics Division, University of Southampton, UK
    Amy V Jones, Andrew Chase, Andrew Collins, Francis Grand & Nicholas C P Cross
  3. Weill Medical College of Cornell University, New York, New York, USA
    Richard T Silver & Y Lynn Wang
  4. Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK
    David Oscier
  5. Haematology Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece
    Katerina Zoi
  6. Department of Pediatrics and Adolescent Medicine, University Hospital Ulm, Ulm, Germany
    Holger Cario
  7. Department of Experimental Anaesthesiology, University Hospital Freiburg, Freiburg, Germany
    Heike L Pahl
  8. III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Germany
    Andreas Reiter

Authors

  1. Amy V Jones
    You can also search for this author inPubMed Google Scholar
  2. Andrew Chase
    You can also search for this author inPubMed Google Scholar
  3. Richard T Silver
    You can also search for this author inPubMed Google Scholar
  4. David Oscier
    You can also search for this author inPubMed Google Scholar
  5. Katerina Zoi
    You can also search for this author inPubMed Google Scholar
  6. Y Lynn Wang
    You can also search for this author inPubMed Google Scholar
  7. Holger Cario
    You can also search for this author inPubMed Google Scholar
  8. Heike L Pahl
    You can also search for this author inPubMed Google Scholar
  9. Andrew Collins
    You can also search for this author inPubMed Google Scholar
  10. Andreas Reiter
    You can also search for this author inPubMed Google Scholar
  11. Francis Grand
    You can also search for this author inPubMed Google Scholar
  12. Nicholas C P Cross
    You can also search for this author inPubMed Google Scholar

Contributions

The study was designed by A.V.J., A. Chase., F.G. and N.C.P.C. A.V.J. performed the laboratory analysis. R.T.S., D.O., K.Z., Y.L.W., H.L.P., H.C. and A.R. provided clinical samples and associated information. A.V.J., A. Chase, A. Collins and N.C.P.C. analyzed the data. N.C.P.C. wrote the first draft of the manuscript and all authors contributed to and approved the final version.

Corresponding author

Correspondence toNicholas C P Cross.

Supplementary information

Rights and permissions

About this article

Cite this article

Jones, A., Chase, A., Silver, R. et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.Nat Genet 41, 446–449 (2009). https://doi.org/10.1038/ng.334

Download citation

This article is cited by

Associated content